Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

NCT ID: NCT03971799

Last Updated: 2025-07-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-08
• Study Completion Date: 2039-12-31

Brief Summary

This phase 1/2 trial aims to determine the safety and feasibility of antiCD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The trial will be done in two phases: Phase 1 will determine the maximum tolerated dose of CD33CART cells using a 3+3 trial design, with dose-escalation for autologous products separated from dose-escalation for an allogeneic arm. Phase 2 is an expansion phase designed to evaluate the rate of response to CD33CART.

Detailed Description

This study consists of two phases. The objectives of Phase 1 and Phase 2 are:

Phase 1:

Autologous Arm: To determine the maximum tolerated dose of lentivirally transduced autologous CD33-redirected CAR-T cells (CD33CART) in children and young adults with relapsed/refractory AML

Allogeneic Arm: To determine the maximum tolerated dose of lentivirally transduced allogeneic CD33-redirected CAR-T cells (ALLO-CD33CART) in children and young adults with post-HSCT relapsed/refractory AML

Phase 2:

To determine the percentage of recipients treated with CD33CART who achieve morphologic remission (<5% blasts in marrow) at Day 28 post-CD33CART cell infusion

Conditions

Acute Myelogenous Leukemia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CD33CART autologous

Patients who receive an autologous CD33CART cell infusion

Group Type: EXPERIMENTAL

CD33CART autologous

Intervention Type: BIOLOGICAL

The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:

LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).

Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable.

CD33 CART allogeneic

Patients who receive an allogeneic CD33CART cell infusion

Group Type: EXPERIMENTAL

CD33CART allogeneic

Intervention Type: BIOLOGICAL

The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:

LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).

Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable.

Interventions

CD33CART autologous

The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:

LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).

Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable.

Intervention Type: BIOLOGICAL

CD33CART allogeneic

The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:

LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).

Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Related Donors: A donor from prior HCT who is fully matched by institutional standards and able to undergo apheresis for T-cell collection.

1. Recipients must have CD33+ AML in second or greater relapse, post-transplant relapse, or have demonstrated chemotherapy-refractory disease (definitions in criteria 2c) to be eligible to participate in this trial.

2. Disease status at the time of enrollment:

1. Recipients in second or greater relapse will be eligible with relapse defined as >5% blasts (bone marrow) after second documented complete remission

2. Any degree of detectable disease post-transplant relapse will be eligible (with flow cytometric confirmation of CD33+ myeloid leukemia of at least 0.1%)

3. Refractory disease is defined as persistent bone marrow involvement with >5% blasts after two courses of induction chemotherapy for patients at initial presentation or >5% bone marrow blasts after one course of re-induction chemotherapy for patients in relapse;

3. CD33 expression must be detected on greater than 50% of the malignant cells by immunohistochemistry or greater than 80% by flow cytometry;

4. Age: Greater than or equal to 1 year of age and less than or equal to 35 years of age at time of enrollment.

5. All recipients must have an allogeneic HCT donor identified with a plan to proceed to HCT conditioning within 6-8 weeks of CD33CART cell infusion;

6. Patients with two prior allogenic donor stem cell transplants must be medically fit for a third allogenic donor stem cell transplant

7. Performance status: > 50% (for recipients > 16 years of age use Karnofsky ≥ 50%; recipients < 16 years of age: Lansky scale ≥ 50%) (see Appendix II). Recipients who are unable to walk because of paralysis, but who are upright in a wheelchair will be considered ambulatory for the purpose of calculating the performance score;

8. Adequate organ function as defined by:

1. Cardiac function: left ventricular ejection fraction (LVEF) ≥ 45% or fractional shortening ≥28%

2. Pulmonary function: baseline oxygen saturation > 92% on room air at rest

3. Hepatic function:

• Total bilirubin < grade 2 bilirubin CTCAE version 5 (<3 x ULN) (except in case of recipients with documented Gilbert's disease > 3 x ULN)
• AST (SGOT)/ALT (SGPT) < 5 x institutional ULN (< grade 3)

4. Renal function: Serum creatinine must be < 1.2 x institutional upper limit of normal (ULN) according to age. If the serum creatinine is greater than 1.2 x ULN, the patient must have a creatinine clearance (CrCl) > 70mL/min/1.73 m2 (measured by 24 hour- urine specimen or radioisotope GFR).

9. Recipients > 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for recipients < 18 years of age. Pediatric recipients will be included in age-appropriate discussion in order to obtain assent; Adults with cognitive impairment who are unable to consent and those with Down Syndrome are also eligible for this protocol with the proper assessments as outlined in Protocol Section 11.2.

10. Enrollment in the NMDP protocol: Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxicity Injuries.

1. Must be the same donor whose cells were used as the source for the patient's most recent stem cell transplant

2. Donors > 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for donors < 18 years of age. Pediatric donors will be included in age-appropriate discussion in order to obtain assent;

3. HLA-matched related sibling (or alternative fully matched relative)

4. Adequate venous access for peripheral apheresis, or without a contradiction to undergoing temporary line placement.

1. For donors who have previously undergone collection for DLI and have a cryopreserved unmobilized product, this may be considered for use as the starting material

Exclusion Criteria

Recipients meeting any of the following criteria are not eligible for participation in the study:

1. Recipients with radiologically-detected CNS chloromas or CNS 3 disease (presence of ≥ 5/μL white blood cells (WBCs) in cerebral spinal fluid (CSF) and cytospin positive for blasts [in the absence of a traumatic lumbar puncture] and/or clinical signs of CNS leukemia such as a cranial nerve palsy from active disease). Recipients with adequately treated CNS leukemia are eligible;

2. Hyperleukocytosis (≥ 50,000 blasts/μL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy;

3. Pregnancy (negative serum or urine pregnancy test must be obtained at time of enrollment for females of childbearing potential and to be repeated 72 hours prior to lymphodepleting chemotherapy regimen);

4. Breast feeding;

5. Sexually active female recipients of childbearing potential and male recipients who are of childbearing potential and are unwilling to practice birth control at time of enrollment and for four months after receiving the lymphodepletion preparative regimen;

6. Active or uncontrolled viral, bacterial or fungal infection. May be receiving ongoing therapy for controlled infection

7. Recent prior therapy:

1. At treatment enrollment:

Patients may be on lower-intensity chemotherapy (e.g., TKIs, venetoclax, hydroxyurea, azacytidine, decitabine or similar agents) at the time of enrollment to prevent disease progression. There is no timing restriction of intrathecal chemotherapy for enrollment.

2. Prior to apheresis: The following wash-out periods apply prior to apheresis

• Systemic chemotherapy ≤ 14 days with the exception of:

• Hydroxyurea: 1 day
• Azacytidine/decitabine and/or venetoclax: 7 days
• Intrathecal chemotherapy > 3 days
• Tyrosine kinase inhibitors: 3 half-lives or 7 days, whichever is shorter (See Appendix XVIII)
• Checkpoint inhibitors or antibody-based therapies: 3 half-lives
• Investigational anti-neoplastic agents: 28 days
• Clofarabine or nitrosureas: 42 days
• Steroid therapy: Not allowed unless at or below physiologic doses (eg, hydrocortisone replacement for prior adrenal insufficiency)
• Radiation therapy: Radiation therapy (including CNS) must have been completed at least 21 days prior to apheresis with the exception of no time restriction if the volume of bone marrow treated is less than 10% and also the recipient has measurable/evaluable disease outside the radiation field.
• CAR T-cell therapy: Excluded unless at least 30 days from prior CAR T-cell infusion and without detectable circulating CAR T-cells **Please see protocol section 2.5.1 for guidance on wash-out parameters prior to initiation of LD chemotherapy

8. Recipients with any history of allogeneic stem cell transplantation are excluded if:

1. Recipients are less than 100 days post-transplant OR

2. Recipients have evidence of ongoing active GVHD and are taking immunosuppressive agents (>0.5 mg/kg/methylprednisolone equivalents or other immunosuppression for GVHD treatment) OR

3. Recipients have received DLI within 30 days prior to enrollment OR

4. Recipients are on active immunosuppression for GVHD prophylaxis (must be off for 30 days prior to enrollment)

5. Recipients who enroll to the ALLO-CD33CART arm must not have had any prior history of > grade 3 acute GVHD or severe chronic GVHD

9. HIV/HBV/HCV Infection:

1. Seropositive for HIV 1 or 2 (Recipients with HIV are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in recipient receiving combination antiretroviral therapy in the future should study results indicate effectiveness)

2. Seropositive for Hepatitis C or positive for Hepatitis B surface antigen (HbsAG)

10. Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the site PI would pose an unacceptable risk to the recipient

11. Active second malignancy will not be eligible with the following exceptions:

1. Treatment-related or secondary CD33+ myeloid malignancy which may potentially benefit from CD33CART (which may be considered for enrollment),

2. Carcinoma in situ of the cervix (which may be considered for enrollment),

3. Recipient is in remission from a prior second malignancy (which may be considered for enrollment)

12. History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin).

1. Pregnancy (negative serum or urine pregnancy test must be obtained at time of enrollment for females of childbearing potential and to be repeated 72 hours prior to apheresis)

2. HIV/HBV/HCV Infection:

1. Seropositive for HIV 1 or 2

2. Seropositive for Hepatitis C or positive for Hepatitis B surface antigen (HbsAG)

3. Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the site PI would pose an unacceptable risk to the donor

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Marrow Donor Program

OTHER

Sponsor Role: collaborator

St. Baldrick's Foundation

OTHER

Sponsor Role: collaborator

Center for International Blood and Marrow Transplant Research

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nirali Shah, MD, MHSc

Role: PRINCIPAL_INVESTIGATOR

National Cancer Institute (NCI)

Richard Aplenc, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital of Philadelphia

Locations

Children's Hospital of Los Angeles

Los Angeles, California, United States

Children's Hospital of Colorado

Aurora, Colorado, United States

National Cancer Institute - NIH

Bethesda, Maryland, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Seattle Children's Hospital/Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Countries

United States

References

Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor N, Tasian SK, Fry TJ. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J Immunother Cancer. 2021 Sep;9(9):e003149. doi: 10.1136/jitc-2021-003149.

Reference Type: DERIVED

PMID: 34531250 (View on PubMed)

Related Links

https://clinicaltrials.gov/ct2/show/NCT02315612?term=CD22+nirali+shah&rank=1

Anti-CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

https://clinicaltrials.gov/ct2/show/NCT03448393?term=CD22+nirali+shah&rank=2

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Other Identifiers

17-CD33CART

Identifier Type: -

Identifier Source: org_study_id